873056-00-9 Usage
Description
(3-nitro-4-propylphenyl)carbamic acid tert-butyl ester is a chemical compound with the formula C12H16N2O5. It is a white to off-white solid with a melting point of 55-58°C and a boiling point of 310-311°C. (3-nitro-4-propylphenyl)carbamic acid tert-butyl ester is known for its chemical compatibility and stability, making it suitable for various industrial applications.
Uses
Used in Pharmaceutical Industry:
(3-nitro-4-propylphenyl)carbamic acid tert-butyl ester is used as an intermediate in the synthesis of pharmaceutical drugs. Its chemical properties and stability make it a valuable component in the development of new medications.
Used in Agrochemical Industry:
(3-nitro-4-propylphenyl)carbamic acid tert-butyl ester is also used as an intermediate in the synthesis of agrochemicals. Its compatibility with other chemicals allows for the creation of effective products for agricultural use.
Safety Precautions:
It is important to handle (3-nitro-4-propylphenyl)carbamic acid tert-butyl ester with caution and use appropriate protective equipment when working with it. This chemical should be stored in tightly sealed containers away from heat, sparks, and open flames to prevent any potential hazards.
Check Digit Verification of cas no
The CAS Registry Mumber 873056-00-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,3,0,5 and 6 respectively; the second part has 2 digits, 0 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 873056-00:
(8*8)+(7*7)+(6*3)+(5*0)+(4*5)+(3*6)+(2*0)+(1*0)=169
169 % 10 = 9
So 873056-00-9 is a valid CAS Registry Number.
873056-00-9Relevant articles and documents
Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
-
, (2015/09/22)
The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.
COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
-
, (2012/04/23)
The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.
